Tarsus Pharmaceuticals Inc
$ 71.14
-3.41%
16 Jan - close price
- Market Cap 3,019,829,000 USD
- Current Price $ 71.14
- High / Low $ 74.06 / 70.99
- Stock P/E N/A
- Book Value 7.89
- EPS -1.99
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.28 %
- 52 Week High 85.25
- 52 Week Low 38.51
About
Tarsus Pharmaceuticals, Inc. is a forward-thinking clinical-stage biopharmaceutical company headquartered in Irvine, California, dedicated to developing groundbreaking therapies for ophthalmic diseases. The firm boasts an innovative pipeline, particularly targeting dry eye disease and other vision-related disorders, addressing critical unmet needs in the ophthalmology market. Through its steadfast commitment to advancing clinical trials and understanding ophthalmic market trends, Tarsus is strategically positioned for growth and to enhance patient outcomes within the evolving healthcare landscape.
Analyst Target Price
$87.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-09 | 2023-08-10 | 2023-05-09 | 2023-03-13 |
| Reported EPS | -0.3 | -0.48 | -0.64 | -0.6 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 | -1.17 | -0.88 | -0.49 |
| Estimated EPS | -0.3645 | -0.38 | -0.63 | -0.8157 | -0.94 | -0.92 | -1.2 | -1.36 | -1.37 | -1.08 | -0.94 | -0.69 |
| Surprise | 0.0645 | -0.1 | -0.01 | 0.2157 | 0.33 | 0.04 | 0.19 | 0.05 | 0.09 | -0.09 | 0.06 | 0.2 |
| Surprise Percentage | 17.6955% | -26.3158% | -1.5873% | 26.4435% | 35.1064% | 4.3478% | 15.8333% | 3.6765% | 6.5693% | -8.3333% | 6.383% | 28.9855% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARS
2026-01-15 12:12:33
Tarsus Pharmaceuticals (NASDAQ:TARS) has a strong financial position, with US$329.6m in net cash as of September 2025, despite using debt in its business. The company holds US$401.8m in cash and US$72.3m in debt. Although Tarsus Pharmaceuticals is not yet profitable, it grew revenue by 182% to US$366m in the last year, and its substantial cash reserves provide a buffer for continued growth.
2026-01-15 10:27:33
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) has seen a significant 417% increase in its share price over the past three years, driven by 100% annual revenue growth, despite the company currently not being profitable. Although the stock experienced a slight dip of 3.7% in the last seven days, its overall long-term performance suggests strong underlying business growth. The article recommends investors consider closer examination of TARS or adding it to their watchlist due to its impressive historical growth and sustained momentum.
2026-01-15 10:01:21
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) has seen its share price increase by 417% over the last three years, significantly outperforming most loss-making companies with its 100% annual revenue growth. Despite a recent 3.7% dip in the last seven days, the company's strong momentum suggests it warrants a closer look from investors. The article highlights that while the recent dip might be concerning for short-term buyers, the long-term performance indicates robust growth.
2026-01-14 12:57:41
BioMarin Pharmaceutical (BMRN) appears to be a better value stock than Tarsus Pharmaceuticals, Inc. (TARS) according to Zacks Equity Research. BMRN holds a stronger Zacks Rank (#2 Buy vs. #3 Hold for TARS) and a superior Value grade of A, as opposed to TARS' D. Key valuation metrics like P/E, PEG, and P/B ratios also indicate BMRN is currently more undervalued.
2026-01-14 10:20:00
This article analyzes momentum shifts for Tarsus Pharmaceuticals Inc. (NASDAQ: TARS), noting weak near- and mid-term sentiment but a strong long-term outlook. It details specific AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights an exceptional risk-reward setup, targeting a 16.2% gain against a 0.3% risk.
2026-01-12 13:57:40
Tarsus Pharmaceuticals, Inc. has released a corporate presentation detailing its progress in eye care, highlighting XDEMVY as the sole FDA-approved treatment for Demodex blepharitis with patent protection until 2038. The company reported record Q3 2025 net sales for XDEMVY and plans to begin a Phase 2 study for Lyme disease prevention in 2026, alongside ongoing global expansion efforts.
